IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes

BACKGROUND: IL-6 receptor (IL-6R) signaling drives development of T cell populations important to type 1 diabetes pathogenesis. We evaluated whether blockade of IL-6R with monoclonal antibody tocilizumab would slow loss of residual β cell function in newly diagnosed type 1 diabetes patients. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Greenbaum, Carla J., Serti, Elisavet, Lambert, Katharina, Weiner, Lia J., Kanaparthi, Sai, Lord, Sandra, Gitelman, Stephen E., Wilson, Darrell M., Gaglia, Jason L., Griffin, Kurt J., Russell, William E., Raskin, Philip, Moran, Antoinette, Willi, Steven M., Tsalikian, Eva, DiMeglio, Linda A., Herold, Kevan C., Moore, Wayne V., Goland, Robin, Harris, Mark, Craig, Maria E., Schatz, Desmond A., Baidal, David A., Rodriguez, Henry, Utzschneider, Kristina M., Nel, Hendrik J., Soppe, Carol L., Boyle, Karen D., Cerosaletti, Karen, Keyes-Elstein, Lynette, Long, S. Alice, Thomas, Ranjeny, McNamara, James G., Buckner, Jane H., Sanda, Srinath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8663550/
https://www.ncbi.nlm.nih.gov/pubmed/34747368
http://dx.doi.org/10.1172/jci.insight.150074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8663550/
https://www.ncbi.nlm.nih.gov/pubmed/34747368
http://dx.doi.org/10.1172/jci.insight.150074

Ejemplares similares